Nordic Pharma has launched Siklos (hydroxycarbamide) for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle cell syndrome.

Hydroxycarbamide is an antineoplastic agent. The specific mechanism of action in the treatment of sickle cell syndrome is not fully understood, but hydroxycarbamide elevates fetal haemoglobin (HbF) concentrations in patients with sickle cell syndrome.

Recently, hydroxycarbamide has shown to be associated with the generation of nitric oxide suggesting that nitric oxide stimulates cyclic guanosine monophosphotase production, activating a protein kinase and increasing the production of HbF.

View Siklos drug record

Further information: Nordic Pharma

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in